The following guidance is based on the best available evidence. The full guideline gives details of the methods and the evidence used to develop the guidance.
Recommendations in this section have been incorporated into suspected cancer (NICE guideline NG12).
220.127.116.11 Carry out tests in primary care (see section 1.1.2) if a woman (especially if 50 or over) reports having any of the following symptoms on a persistent or frequent basis – particularly more than 12 times per month:
persistent abdominal distension (women often refer to this as 'bloating')
feeling full (early satiety) and/or loss of appetite
pelvic or abdominal pain
increased urinary urgency and/or frequency.
18.104.22.168 Consider carrying out tests in primary care (see section 1.1.2) if a woman reports unexplained weight loss, fatigue or changes in bowel habit.
22.214.171.124 Advise any woman who is not suspected of having ovarian cancer to return to her GP if her symptoms become more frequent and/or persistent.
126.96.36.199 Carry out appropriate tests for ovarian cancer (see section 1.1.2) in any woman of 50 or over who has experienced symptoms within the last 12 months that suggest irritable bowel syndrome (IBS), because IBS rarely presents for the first time in women of this age.
188.8.131.52 Measure serum CA125 in primary care in women with symptoms that suggest ovarian cancer (see section 1.1.1).
184.108.40.206 If serum CA125 is 35 IU/ml or greater, arrange an ultrasound scan of the abdomen and pelvis.
220.127.116.11 For any woman who has normal serum CA125 (less than 35 IU/ml), or CA125 of 35 IU/ml or greater but a normal ultrasound:
assess her carefully for other clinical causes of her symptoms and investigate if appropriate
if no other clinical cause is apparent, advise her to return to her GP if her symptoms become more frequent and/or persistent.
18.104.22.168 Measure serum CA125 in secondary care in all women with suspected ovarian cancer, if this has not already been done in primary care.
22.214.171.124 In women under 40 with suspected ovarian cancer, measure levels of alpha fetoprotein (AFP) and beta human chorionic gonadotrophin (beta-hCG) as well as serum CA125, to identify women who may not have epithelial ovarian cancer.
126.96.36.199 Calculate a risk of malignancy index I (RMI I) score (after performing an ultrasound; see recommendation 188.8.131.52) and refer all women with an RMI I score of 250 or greater to a specialist multidisciplinary team.
184.108.40.206 Perform an ultrasound of the abdomen and pelvis as the first imaging test in secondary care for women with suspected ovarian cancer, if this has not already been done in primary care.
220.127.116.11 If the ultrasound, serum CA125 and clinical status suggest ovarian cancer, perform a CT scan of the pelvis and abdomen to establish the extent of disease. Include the thorax if clinically indicated.
18.104.22.168 Do not use MRI routinely for assessing women with suspected ovarian cancer.
Requirement for tissue diagnosis
22.214.171.124 If offering cytotoxic chemotherapy to women with suspected advanced ovarian cancer, first obtain a confirmed tissue diagnosis by histology (or by cytology if histology is not appropriate) in all but exceptional cases.
126.96.36.199 Offer cytotoxic chemotherapy for suspected advanced ovarian cancer without a tissue diagnosis (histology or cytology) only:
in exceptional cases, after discussion at the multidisciplinary team and
after discussing with the woman the possible benefits and risks of starting chemotherapy without a tissue diagnosis.
Methods of tissue diagnosis other than laparotomy
188.8.131.52 If surgery has not been performed, use histology rather than cytology to obtain a tissue diagnosis. To obtain tissue for histology:
use percutaneous image-guided biopsy if this is feasible
consider laparoscopic biopsy if percutaneous image-guided biopsy is not feasible or has not produced an adequate sample.
Use cytology if histology is not appropriate.
184.108.40.206 Perform retroperitoneal lymph node assessment as part of optimal surgical staging in women with suspected ovarian cancer whose disease appears to be confined to the ovaries (that is, who appear to have stage I disease).
220.127.116.11 Do not include systematic retroperitoneal lymphadenectomy (block dissection of lymph nodes from the pelvic side walls to the level of the renal veins) as part of standard surgical treatment in women with suspected ovarian cancer whose disease appears to be confined to the ovaries (that is, who appear to have stage I disease).
18.104.22.168 Do not offer adjuvant chemotherapy to women who have had optimal surgical staging and have low-risk stage I disease (grade 1 or 2, stage Ia or Ib).
22.214.171.124 Offer women with high-risk stage I disease (grade 3 or stage Ic) adjuvant chemotherapy consisting of six cycles of carboplatin.
126.96.36.199 Discuss the possible benefits and side effects of adjuvant chemotherapy with women who have had suboptimal surgical staging and appear to have stage I disease.
Note that recommendations 1.1 and 1.2 in NICE technology appraisal guidance 55 (Guidance on the use of paclitaxel in the treatment of ovarian cancer) are on first-line chemotherapy in the treatment of ovarian cancer.
188.8.131.52 If performing surgery for women with ovarian cancer, whether before chemotherapy or after neoadjuvant chemotherapy, the objective should be complete resection of all macroscopic disease.
184.108.40.206 Offer all women with newly diagnosed ovarian cancer information about their disease, including psychosocial and psychosexual issues, that:
is available at the time they want it
includes the amount of detail that they want and are able to deal with
is in a suitable format, including written information.
220.127.116.11 Ensure that information is available about:
the stage of the disease, treatment options and prognosis
how to manage the side effects of both the disease and its treatments in order to maximise wellbeing
sexuality and sexual activity
fertility and hormone treatment
symptoms and signs of disease recurrence
genetics, including the chances of family members developing ovarian cancer
self-help strategies to optimise independence and coping
where to go for support, including support groups
how to deal with emotions such as sadness, depression, anxiety and a feeling of a lack of control over the outcome of the disease and treatment.
You can also see this guideline in the NICE Pathway on ovarian cancer.
To find out what NICE has said on topics related to this guideline, see our web page on ovarian cancer.
 An urgent referral means that the woman is referred to a gynaecological cancer service within the national target in England and Wales for referral for suspected cancer, which is currently 2 weeks.
 See the appendix for details of how to calculate an RMI I score.
 Lymph node assessment involves sampling of retroperitoneal lymphatic tissue from the para-aortic area and pelvic side walls if there is a palpable abnormality, or random sampling if there is no palpable abnormality.
 Optimal surgical staging constitutes: midline laparotomy to allow thorough assessment of the abdomen and pelvis; a total abdominal hysterectomy, bilateral salpingo-oophorectomy and infracolic omentectomy; biopsies of any peritoneal deposits; random biopsies of the pelvic and abdominal peritoneum; and retroperitoneal lymph node assessment [Winter Roach BA, Kitchener HC, Dickinson HO (2009) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews issue 3: CD004706].